The mechanisms that underlie the pathophysiology of aging, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD) and stroke are not fully understood and have been the focus of intense and constant investigation worldwide. Studies that provide insights on aging and age-related disease mechanisms are critical for advancing novel therapies that promote successful aging and prevent or cure multiple age-related diseases. The April 2019 issue of the journal, "Aging & Disease" published a series of articles that confer fresh insights on numerous age-related conditions and diseases. The age-related topics include the detrimental effect of overweight on energy metabolism and muscle integrity, senoinflammation as the cause of neuroinflammation, the link between systemic C-reactive protein and brain white matter loss, the role of miR-34a in promoting healthy heart and brain, the potential of sirtuin 3 for reducing cardiac and pulmonary fibrosis, and the promise of statin therapy for ameliorating asymptomatic intracranial atherosclerotic stenosis. Additional aging-related articles highlighted the involvement of miR-181b-5p and high mobility group box-1 in hypertension, Yes-associated protein in cataract formation, multiple miRs and long noncoding RNAs in coronary artery disease development, the role of higher meat consumption on sleep problems, and the link between glycated hemoglobin and depression. The topics related to ALS suggested that individuals with higher education and living in a rural environment have a higher risk for developing ALS, and collagen XIX alpha 1 is a prognostic biomarker of ALS. The topics discussed on AD implied that extracellular amyloid β42 is likely the cause of intraneuronal neurofibrillary tangle accumulation in familial AD and traditional oriental concoctions may be useful for slowing down the progression of AD. The article on stroke suggested that inhibition of the complement system is likely helpful in promoting brain repair after ischemic stroke. The significance of the above findings for understanding the pathogenesis in aging, ALS, AD, and stroke, slowing down the progression of aging, ALS and AD, and promoting brain repair after stroke are discussed.
Ashok K. Shetty,Raghavendra Upadhya,Leelavathi N. Madhu, et al. Novel Insights on Systemic and Brain Aging, Stroke, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease[J]. Aging and disease,
2019, 10(2): 470-482.
Franceschi C, Garagnani P, Morsiani C, Conte M, Santoro A, Grignolio A, et al. (2018). The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates. Front Med (Lausanne), 5:61.
Shetty AK, Kodali M, Upadhya R, Madhu LN (2018). Emerging Anti-Aging Strategies - Scientific Basis and Efficacy. Aging Dis, 9:1165-1184.
van den Munckhof ICL, Jones H, Hopman MTE, de Graaf J, Nyakayiru J, van Dijk B, et al. (2018). Relation between age and carotid artery intima-medial thickness: a systematic review. Clin Cardiol, 41:698-704.
Anker D, Santos-Eggimann B, Santschi V, Del Giovane C, Wolfson C, Streit S, et al. (2018). Screening and treatment of hypertension in older adults: less is more? Public Health Rev, 39:26.
Al-Mansour Z, Pang L, Bathini V (2019). Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient? Drugs Aging, 36:1-11.
Weisman A, Fazli GS, Johns A, Booth GL (2018). Evolving Trends in the Epidemiology, Risk Factors, and Prevention of Type 2 Diabetes: A Review. Can J Cardiol, 34:552-564.
Petrash JM (2013). Aging and age-related diseases of the ocular lens and vitreous body. Invest Ophthalmol Vis Sci, 54:ORSF54-59.
Garcia-Layana A, Cabrera-Lopez F, Garcia-Arumi J, Arias-Barquet L, Ruiz-Moreno JM (2017). Early and intermediate age-related macular degeneration: update and clinical review. Clin Interv Aging, 12:1579-1587.
Shao Y, Le W (2019). Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. Mol Neurodegener, 14:3.
Talbott EO, Malek AM, Lacomis D (2016). The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol, 138:225-238.
Roy-O'Reilly M, McCullough LD (2018). Age and Sex Are Critical Factors in Ischemic Stroke Pathology. Endocrinology, 159:3120-3131.
Irwin K, Sexton C, Daniel T, Lawlor B, Naci L (2018). Healthy Aging and Dementia: Two Roads Diverging in Midlife? Front Aging Neurosci, 10:275.
Crous-Bou M, Minguillon C, Gramunt N, Molinuevo JL (2017). Alzheimer's disease prevention: from risk factors to early intervention. Alzheimers Res Ther, 9:71.
Chakrabarti S, Mohanakumar K (2016). Aging and Neurodegeneration: A Tangle of Models and Mechanisms. Aging Dis, 7:111-113.
Konar A, Sing P, Thakur MK (2016). Age-associated Cognitive Decline: Insights into Molecular Switches and Recovery Avenues. Aging Dis, 7:121-129.
Potes Y, Perez-Martinez Z, Bermejo-Millo JC, Rubio-Gonzalez A, Fernandez-Fernandez M, Bermudez M, et al. (2019). Overweight in the elderly induces a switch in energy metabolism that undermines muscle integrity. Aging Dis, 2:217-230.
Chung HY, Kim DH, Lee EK, Chung KW, Chung S, Lee B, et al. (2019). Redefining chronic inflammation in aging and age-related disease: proposal of the senoinflammation concept. Aging Dis, 2:367-382.
Cyprien F, Courtet P, Maller J, Meslin C, Ritchie K, Ancelin M-L, Artero S (2019). Increased C-reactive protein and corpus callosum alterations in older adults. Aging Dis, 2:463-469.
Sarkar NS, Russell AE, Engler-Chiurazzi EB, Porter KN, Simpkins JW (2018). MicroRNAs and the genetic nexus of brain aging, neuroinflammation, neurodegeneration, and brain trauma. Aging Dis, 2:329-352.
Murtha LA, Morten M, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, et al. (2018). The role of pathological aging in cardiac and pulmonary fibrosis. Aging Dis, 2:419-428.
Miao H, Yang Y, Wang H, Huo L, Wang M, Zhou Y, et al. (2019). Intensive lipid-lowering therapy ameliorates asymptomatic intracranial atherosclerosis. Aging Dis, 2:258-266.
Li FJ, Zhang CL, Luo XJ, Peng J, Yang TL (2018). Involvement of the mir-181b-5p/HMGB1 pathway in Ang II-induced phenotypic transformation of smooth muscle cells in hypertension. Aging Dis, 2:231-248.
He Q, Gao Y, Zhou L, Wang T, Yuan Z (2018). Deficiency of Yes-associated protein induces cataract in mice. Aging Dis, 2:293-306.
Zhang Y, Zhang L, Wang Y, Ding, Xue S, Qi H, et al. (2018). MicroRNAs or long noncoding RNAs in diagnosis and prognosis of coronary artery disease. Aging Dis, 2:353-366.
Lana A, Struijk EA, Arias-Fernandez L, Graciani A, Mesas AE, Rodriguez-Artalejo F, et al. (2018). Habitual meat consumption and changes in sleep duration and quality in older adults. Aging Dis, 2:267-277.
Li H, Wang A, Feng W, Zheng D, Gao Q, Tao L, et al. (2018). Prospective study of glycated hemoglobin and trajectories of depressive symptoms: the China health and retirement longitudinal study. Aging Dis, 2:249-257.
Korner S, Kammeyer J, Zapf A, Kuzma-Kozakiewicz M, Piotrkiewicz M, Kuraszkiewicz B, et al. (2018). Influence of environment and lifestyle on incidence and progress of amyotrophic lateral sclerosis in a german ALS population. Aging Dis, 2:205-216.
Calvo AC, Cibreiro GA, Merino PT, Roy JF, Galiana A, Rufián AJet al. (2018). Collagen XIX alpha 1 improves prognosis in amyotrophic lateral sclerosis. Aging Dis, 2:278-292.
Bi C, Bi S, Li B (2018). Processing of mutant β-amyloid precursor protein and the clinicopathological features of familial Alzheimer’s disease. Aging Dis, 2:383-403.
Jeon SG, Song EJ, Lee D, Park J, Nam Y, Kim J-I, et al. (2018). Traditional oriental medicines and Alzheimer’s disease. Aging Dis, 2:307-328.
Ma Y, Liu Y, Zhang Z, Yang GY (2019). Significance of complement system in ischemic stroke: a comprehensive review. Aging Dis, 2:429-462.
Freire MO, Van Dyke TE (2013). Natural resolution of inflammation. Periodontol 2000, 63:149-164.
Chen M, Xu H (2015). Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol, 98:713-725.
Chung HY, Sung B, Jung KJ, Zou Y, Yu BP (2006). The molecular inflammatory process in aging. Antioxid Redox Signal, 8:572-581.
Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S (2017). Inflammaging and 'Garb-aging'. Trends Endocrinol Metab, 28:199-212.
Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, et al. (2009). Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev, 8:18-30.
Luders E, Thompson PM, Toga AW (2010). The development of the corpus callosum in the healthy human brain. J Neurosci, 30:10985-10990.
Di Paola M, Di Iulio F, Cherubini A, Blundo C, Casini AR, Sancesario G, et al. (2010). When, where, and how the corpus callosum changes in MCI and AD: a multimodal MRI study. Neurology, 74:1136-1142.
Cyprien F, Courtet P, Poulain V, Maller J, Meslin C, Bonafe A, et al. (2014). Corpus callosum size may predict late-life depression in women: a 10-year follow-up study. J Affect Disord, 165:16-23.
Cyprien F, Courtet P, Malafosse A, Maller J, Meslin C, Bonafe A, et al. (2011). Suicidal behavior is associated with reduced corpus callosum area. Biol Psychiatry, 70:320-326.
Lebel C, Gee M, Camicioli R, Wieler M, Martin W, Beaulieu C (2012). Diffusion tensor imaging of white matter tract evolution over the lifespan. Neuroimage, 60:340-352.
Li X, Wang Z, Tan L, Wang Y, Lu C, Chen R, et al. (2017). Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice. Mol Ther, 25:140-152.
Wang Y, Veremeyko T, Wong AH, El Fatimy R, Wei Z, Cai W, et al. (2017). Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer's disease. Neurobiol Aging, 51:156-166.
Sarkar S, Jun S, Rellick S, Quintana DD, Cavendish JZ, Simpkins JW (2016). Expression of microRNA-34a in Alzheimer's disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity. Brain Res, 1646:139-151.
Brandenberger C, Muhlfeld C (2017). Mechanisms of lung aging. Cell Tissue Res, 367:469-480.
Newman AB, Arnold AM, Naydeck BL, Fried LP, Burke GL, Enright P, et al. (2003). "Successful aging": effect of subclinical cardiovascular disease. Arch Intern Med, 163:2315-2322.
Murtha LA, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, et al. (2017). The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis. Front Physiol, 8:777.
Chen T, Li J, Liu J, Li N, Wang S, Liu H, et al. (2015). Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-beta/Smad3 pathway. Am J Physiol Heart Circ Physiol, 308:424-434.
Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, et al. (2014). Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab, 20:827-839.
Wong KS, Ng PW, Tang A, Liu R, Yeung V, Tomlinson B (2007). Prevalence of asymptomatic intracranial atherosclerosis in high-risk patients. Neurology, 68:2035-2038.
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. (2016). Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation, 134:441-450.
Hernanz R, Martinez-Revelles S, Palacios R, Martin A, Cachofeiro V, Aguado A, et al. (2015). Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br J Pharmacol, 172:3159-3176.
Firtina Z, Danysh BP, Bai X, Gould DB, Kobayashi T, Duncan MK (2009). Abnormal expression of collagen IV in lens activates unfolded protein response resulting in cataract. J Biol Chem, 284:35872-35884.
Li WC, Kuszak JR, Dunn K, Wang RR, Ma W, Wang GM, et al. (1995). Lens epithelial cell apoptosis appears to be a common cellular basis for non-congenital cataract development in humans and animals. J Cell Biol, 130:169-181.
Nishimoto S, Kawane K, Watanabe-Fukunaga R, Fukuyama H, Ohsawa Y, Uchiyama Y, et al. (2003). Nuclear cataract caused by a lack of DNA degradation in the mouse eye lens. Nature, 424:1071-1074.
Weber C, Noels H (2011). Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 17:1410-1422.
Li HY, Zhao X, Liu YZ, Meng Z, Wang D, Yang F, et al. (2016). Plasma MicroRNA-126-5p is Associated with the Complexity and Severity of Coronary Artery Disease in Patients with Stable Angina Pectoris. Cell Physiol Biochem, 39:837-846.
Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, et al. (2014). MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med, 20:368-376.
Tang Y, Zhang YC, Chen Y, Xiang Y, Shen CX, Li YG (2015). The role of miR-19b in the inhibition of endothelial cell apoptosis and its relationship with coronary artery disease. Sci Rep, 5:15132.
Del Brutto OH, Mera RM, Sedler MJ, Zambrano M, Nieves JL, Cagino K, et al. (2016). The Effect of Age in the Association between Frailty and Poor Sleep Quality: A Population-Based Study in Community-Dwellers (The Atahualpa Project). J Am Med Dir Assoc, 17:269-271.
Ferrie JE, Kivimaki M, Akbaraly TN, Singh-Manoux A, Miller MA, Gimeno D, et al. (2013). Associations between change in sleep duration and inflammation: findings on C-reactive protein and interleukin 6 in the Whitehall II Study. Am J Epidemiol, 178:956-961.
Ferrie JE, Kivimaki M, Akbaraly TN, Tabak A, Abell J, Davey Smith G, et al. (2015). Change in Sleep Duration and Type 2 Diabetes: The Whitehall II Study. Diabetes Care, 38:1467-1472.
Ferrie JE, Shipley MJ, Akbaraly TN, Marmot MG, Kivimaki M, Singh-Manoux A (2011). Change in sleep duration and cognitive function: findings from the Whitehall II Study. Sleep, 34:565-573.
Mesas AE, Guallar-Castillon P, Lopez-Garcia E, Leon-Munoz LM, Graciani A, Banegas JR, et al. (2014). Sleep quality and the metabolic syndrome: the role of sleep duration and lifestyle. Diabetes Metab Res Rev, 30:222-231.
Waller KL, Mortensen EL, Avlund K, Osler M, Fagerlund B, Lauritzen M, et al. (2016). Subjective sleep quality and daytime sleepiness in late midlife and their association with age-related changes in cognition. Sleep Med, 17:165-173.
Pandya M, Altinay M, Malone DA Jr., Anand A (2012). Where in the brain is depression? Curr Psychiatry Rep, 14:634-642.
Hamer M, Batty GD, Kivimaki M (2011). Haemoglobin A1c, fasting glucose and future risk of elevated depressive symptoms over 2 years of follow-up in the English Longitudinal Study of Ageing. Psychol Med, 41:1889-1896.
Maraldi C, Volpato S, Penninx BW, Yaffe K, Simonsick EM, Strotmeyer ES, et al. (2007). Diabetes mellitus, glycemic control, and incident depressive symptoms among 70- to 79-year-old persons: the health, aging, and body composition study. Arch Intern Med, 167:1137-1144.
Wrighten SA, Piroli GG, Grillo CA, Reagan LP (2009). A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta, 1792:444-453.
Masi G, Brovedani P (2011). The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs, 25:913-931.
Lee MM, Reif A, Schmitt AG (2013). Major depression: a role for hippocampal neurogenesis? Curr Top Behav Neurosci, 14:153-179.
Zucchi E, Ticozzi N, Mandrioli J (2019). Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder. Front Neurosci, 13:175.
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. (2017). Amyotrophic lateral sclerosis. Nat Rev Dis Primers, 3:17085.
Brown RH, Al-Chalabi A (2017). Amyotrophic Lateral Sclerosis. N Engl J Med, 377:162-172.
Chio A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group (2011). Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry, 82:740-746.
Floeter MK, Gendron TF (2018). Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in C9orf72. Front Neurol, 9:1063.
Goedert M, Spillantini MG (2006). A century of Alzheimer's disease. Science, 314:777-781.
Mu Y, Gage FH (2011). Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener, 6:85.
Rietze R, Poulin P, Weiss S (2000). Mitotically active cells that generate neurons and astrocytes are present in multiple regions of the adult mouse hippocampus. J Comp Neurol, 424:397-408.
Selkoe DJ (2001). Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A, 98:11039-11041.
Ricciarelli R, Fedele E (2017). The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. Curr Neuropharmacol, 15:926-935.
McQuade A, Blurton-Jones M (2019). Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk. J Mol Biol, .
Arranz AM, De Strooper B (2019). The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. Lancet Neurol, 18:406-414.
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541:481-487.
Liddelow SA, Barres BA (2017). Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity, 46:957-967.
Ho YS, So KF, Chang RC (2011). Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia. Chin Med, 6:15.
Sun ZK, Yang HQ, Chen SD (2013). Traditional Chinese medicine: a promising candidate for the treatment of Alzheimer's disease. Transl Neurodegener, 2:6.
Tian J, Shi J, Zhang X, Wang Y (2010). Herbal therapy: a new pathway for the treatment of Alzheimer's disease. Alzheimers Res Ther, 2:30.
Shi J, Ni J, Lu T, Zhang X, Wei M, Li T, et al. (2017). Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to patients with Alzheimer's disease: a retrospective analysis. BMC Complement Altern Med, 17:533.
Hui S, Yang Y, Peng WJ, Sheng CX, Gong W, Chen S, et al. (2017). Protective effects of Bushen Tiansui decoction on hippocampal synapses in a rat model of Alzheimer's disease. Neural Regen Res, 12:1680-1686.
Ji XF, Chi TY, Liu P, Li LY, Xu JK, Xu Q, et al. (2017). The total triterpenoid saponins of Xanthoceras sorbifolia improve learning and memory impairments through against oxidative stress and synaptic damage. Phytomedicine, 25:15-24.
Adams HP Jr., del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. (2007). Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, 115:e478-534.
Brott T, Bogousslavsky J (2000). Treatment of acute ischemic stroke. N Engl J Med, 343:710-722.
Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS (1997). Acute stroke care and rehabilitation: an analysis of the direct cost and its clinical and social determinants. The Copenhagen Stroke Study. Stroke, 28:1138-1141.
Wang X, Mao X, Xie L, Sun F, Greenberg DA, Jin K (2012). Conditional depletion of neurogenesis inhibits long-term recovery after experimental stroke in mice. PLoS One, 7:e38932.
Alawieh A, Elvington A, Zhu H, Yu J, Kindy MS, Atkinson C, et al. (2015). Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation, 12:247.
Komotar RJ, Kim GH, Otten ML, Hassid B, Mocco J, Sughrue ME, et al. (2008). The role of complement in stroke therapy. Adv Exp Med Biol, 632:23-33.
Komotar RJ, Starke RM, Arias EJ, Garrett MC, Otten ML, Merkow MB, et al. (2009). The complement cascade: new avenues in stroke therapy. Curr Vasc Pharmacol, 7:287-292.
Brennan FH, Lee JD, Ruitenberg MJ, Woodruff TM (2016). Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin Immunol, 28:292-308.